{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Adenocarcinoma&page=15", "query": { "condition": "Breast Adenocarcinoma", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 700, "total_pages": 70, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Adenocarcinoma&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Adenocarcinoma&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T02:00:51.388Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06506955", "title": "Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced/Metastatic Cancer" ], "interventions": [ { "name": "futibatinib", "type": "DRUG" }, { "name": "futibatinib, fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2024-10-01", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-14T02:00:51.388Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06506955" }, { "nct_id": "NCT02393248", "title": "Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer", "Solid Tumor", "Gastric Cancer", "Urothelial Cancer", "Endometrial Cancer", "Multiple Myeloma", "Myeloproliferative Neoplasms", "Breast Cancer", "Cholangiocarcinoma", "UC", "MPN" ], "interventions": [ { "name": "Pemigatinib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 201, "start_date": "2015-02-27", "completion_date": "2021-12-17", "has_results": true, "last_update_posted_date": "2023-01-06", "last_synced_at": "2026-10-14T02:00:51.388Z", "location_count": 19, "location_summary": "Birmingham, Alabama • West Hollywood, California • New Haven, Connecticut + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "West Hollywood", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Port Saint Lucie", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02393248" }, { "nct_id": "NCT07213791", "title": "A Study of LY4337713 in Participants With FAP-Positive Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Neoplasms", "Breast Neoplasms", "Pancreatic Intraductal Neoplasms", "Colorectal Neoplasms", "Esophageal Neoplasms", "Stomach Neoplasms", "Cholangiocarcinoma" ], "interventions": [ { "name": "LY4337713", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2025-10-22", "completion_date": "2033-03", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-14T02:00:51.388Z", "location_count": 20, "location_summary": "Newport Beach, California • Stanford, California • Miami, Florida + 14 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07213791" }, { "nct_id": "NCT00031720", "title": "Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Hot Flashes", "Hot Flushes" ], "interventions": [ { "name": "soy protein", "type": "DIETARY_SUPPLEMENT" }, { "name": "isoflavones", "type": "DIETARY_SUPPLEMENT" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 112, "start_date": "2002-03", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2016-07-13", "last_synced_at": "2026-10-14T02:00:51.388Z", "location_count": 14, "location_summary": "Rockford, Illinois • Elkhart, Indiana • Kokomo, Indiana + 9 more", "locations": [ { "city": "Rockford", "state": "Illinois" }, { "city": "Elkhart", "state": "Indiana" }, { "city": "Kokomo", "state": "Indiana" }, { "city": "La Porte", "state": "Indiana" }, { "city": "South Bend", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00031720" }, { "nct_id": "NCT03495011", "title": "MRI Characterization of Mammographically Detected DCIS", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer, Stage 0" ], "interventions": [ { "name": "Breast MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 122, "start_date": "2018-04-20", "completion_date": "2032-04", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-14T02:00:51.388Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03495011" }, { "nct_id": "NCT02273752", "title": "Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-positive Breast Cancer", "Gastrinoma", "Glucagonoma", "HER2-negative Breast Cancer", "Insulinoma", "Mucositis", "Oral Complications", "Pancreatic Polypeptide Tumor", "Progesterone Receptor-positive Breast Cancer", "Recurrent Breast Cancer", "Recurrent Islet Cell Carcinoma", "Recurrent Renal Cell Cancer", "Somatostatinoma", "Stage III Renal Cell Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2014-11", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-02-03", "last_synced_at": "2026-10-14T02:00:51.388Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02273752" }, { "nct_id": "NCT00694577", "title": "Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ductal Breast Cancer" ], "interventions": [ { "name": "Partial Breast Irradiation using 32 Gy / 8 fractions", "type": "RADIATION" }, { "name": "Partial Breast Irradiation using 36 Gy / 9 fractions", "type": "RADIATION" }, { "name": "Partial Breast Irradiation using 40 Gy /10 fractions", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 324, "start_date": "2003-09", "completion_date": "2021-06", "has_results": true, "last_update_posted_date": "2022-11-14", "last_synced_at": "2026-10-14T02:00:51.388Z", "location_count": 4, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00694577" }, { "nct_id": "NCT00088972", "title": "S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "celecoxib", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 8, "start_date": "2004-11", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2018-08-10", "last_synced_at": "2026-10-14T02:00:51.388Z", "location_count": 9, "location_summary": "Glendale, California • Albuquerque, New Mexico • Houston, Texas + 1 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00088972" }, { "nct_id": "NCT07224464", "title": "The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Solid Tumors", "Stage 4 Cancer" ], "interventions": [ { "name": "The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "New Phase Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2025-12-16", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-14T02:00:51.388Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07224464" }, { "nct_id": "NCT01037790", "title": "Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Solid Tumor", "Adenocarcinoma of the Colon", "Adenocarcinoma of the Rectum", "Adult Central Nervous System Germ Cell Tumor", "Adult Teratoma", "Benign Teratoma", "Estrogen Receptor-negative Breast Cancer", "Estrogen Receptor-positive Breast Cancer", "Familial Testicular Germ Cell Tumor", "HER2-negative Breast Cancer", "HER2-positive Breast Cancer", "Male Breast Cancer", "Ovarian Immature Teratoma", "Ovarian Mature Teratoma", "Ovarian Monodermal and Highly Specialized Teratoma", "Progesterone Receptor-negative Breast Cancer", "Progesterone Receptor-positive Breast Cancer", "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Extragonadal Germ Cell Tumor", "Recurrent Extragonadal Non-seminomatous Germ Cell Tumor", "Recurrent Extragonadal Seminoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Melanoma", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Rectal Cancer", "Stage III Extragonadal Non-seminomatous Germ Cell Tumor", "Stage III Extragonadal Seminoma", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Ovarian Germ Cell Tumor", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Extragonadal Non-seminomatous Germ Cell Tumor", "Stage IV Extragonadal Seminoma", "Stage IV Melanoma", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Rectal Cancer", "Testicular Immature Teratoma", "Testicular Mature Teratoma" ], "interventions": [ { "name": "PD-0332991", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 304, "start_date": "2009-10", "completion_date": "2019-10", "has_results": true, "last_update_posted_date": "2021-03-11", "last_synced_at": "2026-10-14T02:00:51.388Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01037790" } ] }